Is Arch Biopartners Inc. (ACHFF) a Buy, Sell, or Hold?
OTC : ACHFF
Arch Biopartners Inc.
$0.82 USD
$0.09 (11.79%)
- Volume
- 12.9K
- Average Volume
- 27.21K
- Market Capitalization
- $55.71M
- P/E Ratio
- -29.85
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.27
- Year Low
- $0.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.11
Company Overview
OTC
Richard Gabriel Muruve
Biotechnology
Healthcare
ACHFF
6
CA
USD
Liquidity Metrics
-0.75
0.11
0.11
0.11
0.00
Sales & Valuation
-$
0.00
-21.49
-72.82
-0.02
Profitability
-$0.0237
-$1.55M
0.00%
0.00%
70.15%
-559.74%
P/E Metrics
-29.85
0.57
0.57
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-124.56
2/9
-$3.65M
$464.36K
$4.12M
-$2.53M
Key Metrics (TTM)
$74.3M
0.00
-31.88
0.11
70.15%
266.32%
-3.65%
-1.52%
-4298 days
Company Executives
| Name | Title |
|---|---|
| Richard Gabriel Muruve | Co-Founder, Chief Executive Officer, President & Director |
| Andrew Bishop | Chief Financial Officer & Director |
| Daniel Abraham Muruve | Co-Founder, Chief Science Officer & Member of Scientific Advisory Board |
| Justin MacDonald | Co-Founder & Principal Scientist |
| Paul Beck | Co-Founder & Principal Scientist |
| Aaron Benson | Director of Communications & Clinical Data Management |
Poll Results
No votes yet today — be the first to share your view!
About Arch Biopartners Inc. (OTC:ACHFF) Stock
Arch Biopartners Inc. is a biotechnology company focused on developing innovative technologies with significant medical and commercial potential. Their primary endeavor involves advancing Metablok, a lead drug candidate designed to treat or prevent dipeptidase-1 (DPEP-1) mediated inflammation in critical organs like the lungs, liver, and kidneys. This inflammation is a key factor in organ damage or failure, often seen in severe conditions such as sepsis and COVID-19. Additionally, the company is progressing with AB569, an investigational drug aimed at combating or deterring antibiotic-resistant bacterial infections, predominantly through topical application for wounds. Further expanding their portfolio, Arch Biopartners is developing Borg, a peptide-based technology that interfaces with so ... lid surfaces to inhibit biofilm formation and reduce corrosion. Another distinct project is MetaMx, which consists of synthetic molecules specifically engineered to target brain tumor initiating cells and aggressive glioma cells. The company is headquartered in Toronto, Canada.
Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program
2026-07-17 08:20:00
TORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company's pre-IND IL-32 chronic kidney disease (“CKD”) program.
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
2026-07-08 02:00:00
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair.
2026-06-04 07:41:00
TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the 2026 American Diabetes Association Thought Leadership Series at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films.
2026-05-22 06:50:00
TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company's ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).
Frequently Asked Questions
-
What is the current Arch Biopartners Inc. (ACHFF) stock price?
-
Arch Biopartners Inc.(OTC:ACHFF) stock price is $0.82 in the last trading session. During the trading session, ACHFF stock reached the peak price of $1.27 while $0.288 was the lowest point it dropped to. The percentage change in ACHFF stock occurred in the recent session was 11.79% while the dollar amount for the price change in ACHFF stock was $0.09.
-
ACHFF's industry and sector of operation?
-
The OTC listed ACHFF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ACHFF?
-
Richard Gabriel Muruve | Co-Founder, Chief Executive Officer, President & Director
Andrew Bishop | Chief Financial Officer & Director
Daniel Abraham Muruve | Co-Founder, Chief Science Officer & Member of Scientific Advisory Board
Justin MacDonald | Co-Founder & Principal Scientist
Paul Beck | Co-Founder & Principal Scientist -
How many employees does ACHFF have?
-
Number of ACHFF employees currently stands at 6. ACHFF operates from 545 King Street West, Toronto, ON M5V 1M1, CA.
-
Link for ACHFF official website?
-
Official Website of ACHFF is: https://www.archbiopartners.com
-
How do I contact ACHFF?
-
ACHFF could be contacted at phone #647-428-7031 and can also be accessed through its website. ACHFF operates from 545 King Street West, Toronto, ON M5V 1M1, CA.
-
How many shares of ACHFF are traded daily?
-
The average number of ACHFF shares traded daily for last 3 months was 27.21K.
-
What is the market cap of ACHFF currently?
-
The market value of ACHFF currently stands at $55.71M with its latest stock price at $0.82